Literature DB >> 7561342

Increased expression of complement receptor type 1 (CR1, CD35) on human peripheral blood T lymphocytes after polyclonal activation in vitro.

A Rodgaard1, B S Thomsen, G Bendixen, K Bendtzen.   

Abstract

The receptor for C3b and C4b--complement receptor type 1 (CR1, CD35)--is present on a variety of cell types including erythrocytes, phagocytic cells, B lymphocytes and a small subpopulation of T lymphocytes. The function of the receptor varies according to the different cell types, but on T lymphocytes the function is as yet not known. The present study concerns the influence of polyclonal stimulation on CR1-expressing T lymphocytes. Incubation with PHA resulted in a dose-dependent increase in the number of CR1-positive T lymphocytes. The CR1-expression T lymphocytes were found in both the CD4- and the CD8-positive subpopulation, but a significant stimulatory increase was only found in the CD4-positive population. A significant increase in the number of CR1-expressing T lymphocytes was found when monocytes were present during stimulation, indicating an importance of monocytes and/or monocyte products. However, the increase was not regulated by arachidonic acid metabolites of the cyclo-oxygenase pathway as indomethacin failed to inhibit the increase. Neither did rIL-1 alpha, rIL-1 beta, rTNF alpha nor rIL-6 alter the number of CR1-expressing T lymphocytes. The results of this study indicate a role for CR1 on T lymphocytes in the regulation of the immune system.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7561342     DOI: 10.1007/BF02918498

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  18 in total

1.  Multiparametric flow cytometric analysis of the kinetics of surface molecule expression after polyclonal activation of human peripheral blood T lymphocytes.

Authors:  R Biselli; P M Matricardi; R D'Amelio; A Fattorossi
Journal:  Scand J Immunol       Date:  1992-04       Impact factor: 3.487

Review 2.  Human erythrocyte complement receptor type one (CR1): expression, function and role in the pathogenesis of inflammatory connective tissue diseases.

Authors:  B S Thomsen
Journal:  Dan Med Bull       Date:  1988-10

3.  Human anti-interleukin 1 alpha antibodies.

Authors:  M B Hansen; M Svenson; K Bendtzen
Journal:  Immunol Lett       Date:  1991-09       Impact factor: 3.685

4.  Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens.

Authors:  M Reynes; J P Aubert; J H Cohen; J Audouin; V Tricottet; J Diebold; M D Kazatchkine
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

5.  Distribution and quantitative expression of the complement receptor type 1 (CR1) on human peripheral blood T lymphocytes.

Authors:  D D Yaskanin; L F Thompson; F J Waxman
Journal:  Cell Immunol       Date:  1992-06       Impact factor: 4.868

6.  Role of C3b receptors in the enhancement of interleukin-2-dependent T-cell proliferation.

Authors:  A Erdei; E Spaeth; J Alsenz; E Rüde; T Schulz; J Gergely; M P Dierich
Journal:  Mol Immunol       Date:  1984-12       Impact factor: 4.407

7.  Characterization of human T lymphocytes that express the C3b receptor.

Authors:  J G Wilson; T F Tedder; D T Fearon
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

8.  Human urine deoxyribonuclease increases endogenous thymidine in the mouse thymocyte interleukin 1 assay: an artificial interleukin-1 inhibitor.

Authors:  M Svenson; K Bendtzen
Journal:  Cytokine       Date:  1989-11       Impact factor: 3.861

9.  Human T lymphocytes expressing the C3b/C4b complement receptor type one (CR1, CD35) belong to Fc gamma receptor-positive CD4-positive T cells.

Authors:  J H Cohen; J P Aubry; J P Revillard; J Banchereau; M D Kazatchkine
Journal:  Cell Immunol       Date:  1989-07       Impact factor: 4.868

10.  Complement receptor type 1 (CR1, CD35) expression on peripheral T lymphocytes: both CD4- and CD8-positive cells express CR1.

Authors:  A Rødgaard; L D Christensen; B S Thomsen; A Wiik; G Bendixen
Journal:  Complement Inflamm       Date:  1991
View more
  6 in total

1.  B-cell antigens within normal and activated human T cells.

Authors:  G P Sandilands; M Perry; M Wootton; J Hair; I A More
Journal:  Immunology       Date:  1999-03       Impact factor: 7.397

Review 2.  Development of complement therapeutics for inhibition of immune-mediated red cell destruction.

Authors:  Karina Yazdanbakhsh
Journal:  Transfusion       Date:  2005-08       Impact factor: 3.157

3.  Immunogenetics of Lupus Erythematosus.

Authors:  Begüm Ünlü; Ümit Türsen; Navid Jabalameli; Fahimeh Abdollahimajd; Fateme Rajabi
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  T cell activation by soluble C1q-bearing immune complexes: implications for the pathogenesis of rheumatoid arthritis.

Authors:  K Jiang; Y Chen; C-S Xu; J N Jarvis
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

5.  A novel mouse model expressing human forms for complement receptors CR1 and CR2.

Authors:  Harriet M Jackson; Kate E Foley; Rita O'Rourke; Timothy M Stearns; Dina Fathalla; B Paul Morgan; Gareth R Howell
Journal:  BMC Genet       Date:  2020-09-09       Impact factor: 2.797

Review 6.  Complement Receptor 1: disease associations and therapeutic implications.

Authors:  Rohan Khera; Nibhriti Das
Journal:  Mol Immunol       Date:  2008-11-11       Impact factor: 4.407

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.